Apolipoprotein E modifies the CNS response to injury via a histamine-mediated pathway

Neurological Research

Volumn 29, Issue 3, 2007, Pages 243-250

  Mace, Brian E ^a   Wang, Haichen ^a   Lynch, John R ^a   Moss, Jason ^a   Sullivan, Patrick ^a   Colton, Heidi ^b   Morgan, Kevin ^b,c   Renauld, Jean Christophe ^d   Laskowitz, Daniel T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

^c Sanofi Aventis   (United States)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Apolipoprotein E; Closed head injury; Histamine; Inflammation; Interleukin 9 receptor

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; HISTAMINE; INTERLEUKIN 9 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; CELL DIFFERENTIATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEGRANULATION; DISEASE ASSOCIATION; ENCEPHALITIS; GENE EXPRESSION; HEAD INJURY; HISTAMINE RELEASE; IMMUNOHISTOCHEMISTRY; MALE; MAST CELL; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; TRANSGENIC MOUSE; UPREGULATION; WILD TYPE;

ANALYSIS OF VARIANCE; ANIMALS; APOLIPOPROTEINS E; CENTRAL NERVOUS SYSTEM; CRANIOCEREBRAL TRAUMA; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; HISTAMINE; INTERLEUKIN-9; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REACTION TIME; RECEPTORS, INTERLEUKIN-9; SIGNAL TRANSDUCTION; TIME FACTORS; UP-REGULATION;

EID: 34249058360     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164107X158974     Document Type: Article

References (39)

1. Mahley RW. apolipoproteinE: Cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622-630
2. Laskowitz DT, Sheng H, Bart RD, et al. Apolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia. J Cereb Blood Flow Metab 1997; 17: 753-758
3. Sheng H, Laskowitz DT, Mackensen GB, et al. Apolipoprotein E deficiency worsens outcome from global cerebral ischemia in the mouse. Stroke 1999; 30: 1118-1124
4. Chen Y, Lomnitski L, Michaelson DM, et al. Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury. Neuroscience 1997; 80: 1255-1262
5. Lynch JR, Pineda JA, Morgan D, et al. Apolipoprotein E affects the central nervous system response to injury and the development of cerebral edema. Ann Neurol 2002; 51: 113-117
6. Weisgraber KH. Apolipoprotein E: Structure-function relationships. Adv Protein Chem 1994; 45: 249-302
7. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923
8. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: High-avidity binding to beta- amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 1977-1981
9. Alberts MJ, Graffagnino C, McClenny C, et al. ApoE genotype and survival from intracerebral hemorrhage. Lancet 1995; 346: 575-579
10. Sorbi S, Nacmias B, Piacentini S, et al. ApoE as a prognostic factor for post-traumatic coma. Nat Med 1995; 1: 852
11. Teasdale GM, Nicoll JA, Murray G, et al. Association of apolipoprotein E polymorphism with outcome after head injury. Lancet 1997; 350: 1069-1071
12. Tardiff BE, Newman MF, Saunders AM, et al. Preliminary report of a genetic basis for cognitive decline after cardiac operations. Ann Thorac Surg 1997; 64: 715-720
13. Sheng H, Laskowitz DT, Bennett E, et al. Apolipoprotein E isoformspecific differences in outcome from focal ischemia in transgenic mice. J Cereb Blood Flow Metab 1998; 18: 361-366
14. Sabo T, Lomnitski L, Nyska A, et al. Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: The allele E3 is neuroprotective whereas E4 increases fatalities. Neuroscience 2000; 101: 879-884
15. Horsburgh K, McCulloch J, Nilsen M, et al. Increased neuronal damage and apoE immunoreactivity in human apolipoprotein E, E4 isoform-specific, transgenic mice after global cerebral ischaemia. Eur J Neurosci 2000; 12: 4309-4017
16. Barger SW, Harmon AD. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 1997; 388: 878-881
17. Laskowitz DT, Goel S, Bennett ER, et al. Apolipoprotein E suppresses glial cell secretion of TNF alpha. J Neuroimmunol 1997; 76: 70-74
18. Laskowitz DT, Thekdi AD, Thekdi SD, et al. Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp Neurol 2001; 167: 74-85
19. Lynch JR, Tang W, Wang H, et al. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem 2003; 278: 48529-48533
20. Lynch JR, Morgan D, Mance J, et al. Apolipoprotein E modulates glial activation and endogenous central nervous system inflammatory response. J Neuroimmunol 2001; 114: 107-113
21. Lynch JR, Wang H, Mace B, et al. A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. Exp Neurol 2005; 192: 109-116
22. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res 1990; 31: 545-548
23. Kepler TB, Crosby L, Morgan KT. Normalization and analysis of DNA microarray data by self-consistency and local regression. Genome Biol 2002; 3: RESEARCH0037
24. Uyttenhove C, Simpson RJ, Van Snick J. Functional and. structural characterization of P40, a mouse glycoprotein with T-cell growth factor activity. Proc Natl Acad Sci USA 1988; 85: 6934-6938
25. Hamm RJ, Pike BR, O'Dell DM, et al. The rotarod test: An evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J Neurotrauma 1994; 11: 187-196
26. Patkai J, Mesples B, Dommergues MA, et al. Deleterious effects of IL-9 activated mast cell and neuroprotection by antihistamine drugs in the developing mouse brain. Pediat Res 2001; 50: 222-230
27. Friedman G, Froom P, Sazbon L, et al. Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology 1999; 52: 244-248
28. Jordan BD, Relkin NR, Ravdin LD, et al. Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. JAMA 1997; 278: 136-140
29. Kutner KC, Erlanger DM, Tsai J, et al. Lower cognitive performance of older football players possessing apolipoprotein E epsilon4. Neurosurgery 2000; 47: 651-657
30. McCarron MO, Weir CJ, Muir KW, et al. Effect of apolipoprotein E genotype on in-hospital mortality following intracerebral haemorrhage. Acta Neurol Scand 2003; 107: 106-109
31. Schiefermeier M, Kollegger H, Madl C, et al. Apolipoprotein E polymorphism: Survival and neurological outcome after cardiopulmonary resuscitation. Stroke 2000; 31: 2068-2073
32. Schmidt S, Barcellos LF, DeSombre K, et al. Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. Am J Hum Genet 2002; 70: 708-717
33. Demoulin JB, Renauld JC. Interleukin 9 and its receptor: An overview of structure and function. Int Rev Immunol 1998; 16: 345-364
34. Dines KC, Powell HC. Mast cells interaction with the nervous system: Relationship to mechanism of disease. J Neuropathol Exp Neurol 1997; 56: 627-640
35. Sztriha L, Joo F, Szerdahelyi P. Histamine H2-receptors participate in the formation of brain edema induced by kainic acid in rat thalamus. Neurosci Lett 1987; 75: 334-338
36. Breitner JC, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995; 16: 523-530
37. Bart RD, Sheng H, Laskowitz DT, et al. Regional CBF in apolipoprotein E-deficient and wild type mice during focal cerebral ischemia. Neuroreport 1998; 9: 2615-2620
38. Knouff C, Hinsdale ME, Mezdour H, et al. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest 1999; 130: 1579-1586
39. Anthony JC, Breitner JC, Zandi PP, et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: The Cache County study. Neurology 2000; 54: 2066-2071